Home > Gastroenterology > GLP-1 receptor agonists may increase risk of gallbladder or biliary disease

GLP-1 receptor agonists may increase risk of gallbladder or biliary disease


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
JAMA Internal Medicine
Reuters Health - 29/03/2022 - Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may raise the risk of gallbladder or biliary diseases, especially at higher doses and when taken for longer periods of time and when the indication is weight loss, according to a systematic review and meta-analysis.  Based on the findings, "physicians and patients should be concerned about the risks of gallbladder or biliary diseases with using GLP-1 RAs for treatment in clinical practice," researchers write in JAMA Internal Medicine.  The analysis, by Dr. Huabing Zhang and colleagues from the Chinese Academy of Medical Sciences and Peking Union Medical College, in Beijing, incl...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on